Reducing conjugative plasmids in bacteria
The present invention provides methods and compositions to reduce prevalence of plasmids in microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. Means are provided to reduce the copy numbers of antibiotic resistance genes, and to confer phage binding to cells lacking receptors for those phage.
1. A method for reducing the number of a recipient bacterial population comprising the steps of:
(a) transferring a conjugative plasmid from a donor bacterial population to the recipient bacterial population, wherein the conjugative plasmid transfers between bacterial cells and encodes a phage receptor that binds a tectivirus phage, wherein the transferring comprises contacting the donor bacterial population with the recipient bacterial population, and wherein the recipient bacterial population is not susceptible to binding by the tectivirus phage until the recipient bacterial population expresses the phage receptor; and
(b) contacting the recipient bacterial population with the tectivirus phage that binds to the phage receptor, wherein said contacting localizes the tectivirus phage to recipient bacteria expressing the tectivirus phage receptor,
thereby reducing the number of the recipient bacterial population.
2. The method of claim 1 , wherein the plasmid comprises a recombinant expression cassette comprising a strong promoter functional in the recipient bacterial population operably linked to a sequence encoding the phage receptor.
3. The method of claim 1 , wherein the plasmid is selected from the group consisting of:
F, R386, R1, Col B-K99, Col B-K166, R124, R62, R64, R483, R391, R46, R724, RP4, RK2, R751, RSF1010, R401, R388, and S-a.
4. The method of claim 1 , wherein the plasmid is selected from the group consisting of:
Inc group N, P, and W.
5. The method of claim 1 , wherein the phage is selected from the group consisting of:
PRD1, PRR1, AP50, Bam35, NS11, PR3, PR4, PR5, PR722, L17, P37-14 pGIL01, and GIL16.
6. The method of claim 1 , wherein the donor bacterial population comprises bacteria from at least one genus selected from the group consisting of:
Escherichia, Pseudomonas, Salmonella, Proteus, Vibrio, Acinetobacter, Bacillus , and Micrococcus.
7. The method of claim 1 , wherein the recipient bacterial population comprises bacteria from at least one genus selected from the group consisting of:
Escherichia, Pseudomonas, Salmonella, Proteus, Vibrio, Acinetobacter, Bacillus , and Micrococcus.
8. The method of claim 1 , wherein said recipient bacterial population is part of a heterologous population of bacteria for at least one step of the method.
9. The method of claim 1 , wherein the plasmid is selected from the group consisting of: F, R64, R391, R46, R724, RP4, RK2, RSF1010, R388, and S-a.
10. The method of claim 1 , wherein the phage is selected from the group consisting of: PRD1, AP50, Bam35, PR722, L17, and GIL16.
11. The method of claim 1 , wherein the number of recipient bacteria expressing the tectivirus phage receptor is reduced by at least 90%.
12. The method of claim 1 , wherein the number of recipient bacteria expressing the tectivirus phage receptor is reduced by at least 103-fold.
13. The method of claim 1 , wherein the donor bacteria is selected from Salmonella, Proteus, Vibrio, Acinetobacter, Bacillus , and Micrococcus.
14. The method of claim 1 , wherein the recipient bacteria is selected from Salmonella, Proteus, Vibrio, Acinetobacter, Bacillus , and Micrococcus.
15. The method of claim 1 , wherein the recipient bacteria is Salmonella.
16. The method of claim 1 , wherein the recipient bacteria is Xanthomonas.
17. The method of claim 1 , wherein the method is carried out in vitro.